ADMA Biologics Surges to 331st in Daily Rankings with 2.50 Billion Turnover

On April 28, 2025, ADMA Biologics (ADMA) saw a significant surge in trading volume, with a turnover of 2.50 billion, marking a 337.63% increase from the previous day. This substantial rise placed ADMA at the 331st position in the daily stock market rankings. The stock price of ADMA Biologics rose by 12.12%.

ADMA Biologics, Inc. has received approval from the U.S. Food and Drug Administration (FDA) for its innovative production yield enhancement process. This approval is a significant milestone for the company, as it is expected to increase production output by approximately 20% from the same plasma volume. The newly approved process is anticipated to benefit both of ADMA's lead immune globulin products, ASCENIV and BIVIGAM.

This FDA approval positions ADMA as the first U.S. producer of plasma-derived products to achieve regulatory approval for such an innovative yield enhancement production process. The company's yield enhancement process has demonstrated the ability to increase production, which is expected to accelerate revenue growth by the end of 2025.